Acquisition of Cizzle Biotechnology, change of name and admission to the Main Market of the LSE
May 2021
Having originally listed on AIM in April 2019, Bould Opportunities was classified as an AIM rule 15 Cash Shell and as such was required to make an acquisition or acquisitions which constitute a reverse takeover under AIM Rule 14. This led to the Acquisition of Cizzle Biotechnology Limited.
Founded in 2006 by Professor Coverley, Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer. It is a spin-out from the University of York and was initially funded by Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members, who with management, invested in the project to support the development of a prototype blood test.
Admission to Trading on the Official List
On 14th May 2021 dealings commenced by way of an Acquisition of Cizzle Biotechnology Limited, Placing of 22,000,000 New Ordinary Shares at 10p per share, Change of name to Cizzle Biotechnology Holdings PLC and Share Reorganisation.
The Perivan shareholder communications team were delighted to work with Allenby Capital who were appointed Financial Adviser on the successful publication of the 180-page prospectus.
For further information click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
